Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clindamycin + benzoyl peroxide is a fixed-dose topical combination used primarily for the treatment of acne vulgaris in patients aged 12 years and older. It combines two active ingredients with complementary mechanisms: - **Clindamycin** is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, thereby preventing *Cutibacterium acnes* (formerly *Propionibacterium acnes*) from growing and replicating. - **Benzoyl peroxide** is an antiseptic and keratolytic agent that kills *C. acnes* by releasing free radical oxygen species to oxidize bacterial proteins. It also helps reduce sebum production and prevents clogged pores. This dual mechanism targets both the microbial cause of acne and associated inflammation while reducing resistance risk due to their different modes of action[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + benzoyl peroxide.